Precision BioSciences/DTIL

$12.72

-30.86%
-
1D1W1MYTD1YMAX

About Precision BioSciences

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. ARCUS is a natural homing endonuclease which allows precise gene editing, such as gene insertions, gene excision, and gene elimination. ARCUS is also relatively small size which potentially allows delivery to a range of cells and tissues using viral and non-viral gene delivery methods. ARCUS uses sequence-specific deoxyribonucleic acid (DNA)-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues. The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-HbE, PBGENE-DMD, PBGENE-LLY2, PBGENE-LLY3, iECURE-OTC, and PBGENE-PMM. PBGENE-HBV is designed for the treatment of chronic hepatitis B virus (HBV).

Ticker

DTIL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Amoroso

Employees

115

Headquarters

Durham, United States

DTIL Metrics

BasicAdvanced
$51.69M
Market cap
-
P/E ratio
-$19.67
EPS
1.56
Beta
-
Dividend rate

What the Analysts think about DTIL

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 4 analysts.
519.1% upside
High $90.00
Low $60.00
$12.72
Current price
$78.75
Average price target

DTIL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-61.06% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$13.1M
-33.5%
Net income
$-8M
-32.2%
Profit margin
-61.06%
1.95%

DTIL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.92%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$7.80
-$6.90
-$3.00
-$2.10
-
Expected
-$6.23
-$6.85
-$7.32
-$4.88
-$1.40
Surprise
25.3%
0.73%
-59.02%
-56.92%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Precision BioSciences stock

Buy or sell Precision BioSciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing